Podcasts about Prostate cancer

Preventing and Treating Erectile Dysfunction (ED) In the 2nd half of this episode learn about dietary factors, including the exclusion of meat, dairy and eggs, that can help you live without pain from arthritis. Written by Thomas Campbell, MD at the T. Colin Campbell Center for Nutrition Studies. #vegan #plantbased #veganpodcast #plantbasedpodcast #plantbasedbriefing #ed #erectiledysfunction #heartdisease   ======================== Original post: https://nutritionstudies.org/preventing-and-treating-erectile-dysfunction-e-d/  ========================== Related Episodes: 1106, 1064/5, 755, 602, 583/4, 494, 473, 148 1106: From Bacon-Lover to Vegan: My Unlikely Journey to Better Health https://plantbasedbriefing.libsyn.com/1106-from-bacon-lover-to-vegan-my-unlikely-journey-to-better-health-by-craig-milton-at-forksoverknivescom  1064: [Part 1] Diet, Lifestyle And Prostate Cancer by Dr. Shireen Kassam https://plantbasedbriefing.libsyn.com/1064-part-1-diet-lifestyle-and-prostate-cancer-by-dr-shireen-kassam-at-plantbasedhealthprofessionalscom  1065: [Part 2] Diet, Lifestyle And Prostate Cancer https://plantbasedbriefing.libsyn.com/1065-part-2-diet-lifestyle-and-prostate-cancer-by-dr-shireen-kassam-at-plantbasedhealthprofessionalscom 755: New Study: Plant-Based Foods Could Improve Men's Sexual Health After Prostate Cancer Treatment https://plantbasedbriefing.libsyn.com/743-new-study-plant-based-foods-could-improve-mens-sexual-health-after-prostate-cancer-treatment-by-charlotte-pointing-at-vegnewscom 602: How Erectile Dysfunction Can Save a Life (and Be Reversed) https://plantbasedbriefing.libsyn.com/602-how-erectile-dysfunction-can-save-a-life-and-be-reversed-by-joel-kahn-md-at-forksoverknivescom 584: [Part 2] What Is Cholesterol? How It Works, Foods to Avoid, and the Truth About HDL https://plantbasedbriefing.libsyn.com/584-part-2-what-is-cholesterol-how-it-works-foods-to-avoid-and-the-truth-about-hdl-by-courtney-davison-at-forksoverknivescom 494: Milk Drinkers See 60% Higher Rates of Prostate Cancer https://plantbasedbriefing.libsyn.com/494-milk-drinkers-see-60-higher-rates-of-prostate-cancer-by-meghan-edwards-at-forksoverknivescom 473: Lower Rates of Erectile Dysfunction Linked to Plant-Based Diets https://plantbasedbriefing.libsyn.com/473-lower-rates-of-erectile-dysfunction-linked-to-plant-based-diets-by-megan-edwards-at-forksoverknivescom 148: Fight Erectile Dysfunction and 4 More Reasons to Go Plant Based This Movember https://plantbasedbriefing.libsyn.com/148-fight-erectile-dysfunction-and-4-more-reasons-to-go-plant-based-this-movember-by-josh-cullimore-md-at-pcrmorg   use search feature at https://www.plantbasedbriefing.com/episodes-search      ========================= The T. Colin Campbell Center for Nutrition Studies was established to extend the impact of Dr. Campbell's life changing research findings. For decades, T. Colin Campbell, PhD, has been at the forefront of nutrition education and research. He is the coauthor of the bestselling book, The China Study, and his legacy, the China Project, is one of the most comprehensive studies of health and nutrition ever conducted. Their mission is to promote optimal nutrition through science-based education, advocacy, and research. By empowering individuals and health professionals, we aim to improve personal, public, and environmental health. ====================== FOLLOW THE SHOW ON: YouTube: https://www.youtube.com/@plantbasedbriefing     Spotify: https://open.spotify.com/show/2GONW0q2EDJMzqhuwuxdCF?si=2a20c247461d4ad7 Apple Podcasts: https://podcasts.apple.com/us/podcast/plant-based-briefing/id1562925866 Your podcast app of choice: https://pod.link/1562925866 Facebook: https://www.facebook.com/PlantBasedBriefing   LinkedIn: https://www.linkedin.com/company/plant-based-briefing/ 

Charity Prostate Cancer UK says some people are being treated when they don't need to be. Learn about this news story with Phil and Pippa.Find full subtitles and a worksheet for this episode at: https://www.bbc.co.uk/learningenglish/english/features/learning-english-from-the-news_2025/250813FIND BBC LEARNING ENGLISH HERE: Visit our website ✔️ https://www.bbc.co.uk/learningenglish Follow us ✔️ https://www.bbc.co.uk/learningenglish/followusSUBSCRIBE TO OUR NEWSLETTER: ✔️ https://www.bbc.co.uk/learningenglish/newslettersFor more of our podcasts, search for these in your podcast app: ✔️ Learning English for Work ✔️ Learning Easy English ✔️ Learning English Grammar ✔️ Learning English Stories ✔️ 6 Minute English ✔️ Learning English Conversations ✔️ Learning English Vocabulary

BUFFALO, NY – August 11, 2025 – A new #researchpaper was #published in Volume 16 of Oncotarget on July 25, 2025, titled “Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancer.” In this study, researchers led by first author Aiden Deacon and corresponding author Justin Hwang from the University of Minnesota-Twin Cities investigated a group of genes known as the R-spondin family (RSPO1/2/3/4) in advanced prostate cancer (PC). The RSPO gene family regulates Wnt signaling, a pathway involved in cancer progression. Prostate cancer is the most common cancer among men in the United States and becomes especially dangerous when it spreads beyond the prostate. Most patients are treated with hormone therapies that target the androgen receptor; however, many tumors eventually become resistant. The research team analyzed thousands of tumor samples and found that RSPO2 alterations were more common than changes in other R-spondin genes or even some well-known cancer-related genes like CTNNB1 and APC. RSPO2 amplification occurred in over 20% of metastatic prostate cancer. Patients with these alterations showed signs of more aggressive disease, including higher mutation rates and greater tumor complexity. Using laboratory models, the team discovered that RSPO2 increases cancer cell growth and triggers a biological process called epithelial-mesenchymal transition (EMT). EMT is known to promote tumor spread and resistance to standard treatments. Unlike other genes in the same pathway, RSPO2 also appeared to reduce the activity of androgen receptor genes, suggesting it drives a type of prostate cancer that no longer relies on hormones for growth. “In cell lines, RSPO2 overexpression caused up-regulation of EMT pathways, including EMT-regulatory transcription factors ZEB1, ZEB2, and TWIST1.” Importantly, RSPO2 showed structural differences from other R-spondin proteins, which may allow researchers to design drugs that specifically block its activity. Current therapies targeting the Wnt pathway are limited, and there are no approved drugs that inhibit RSPO2. However, this study highlights RSPO2 as a promising therapeutic target, especially for patients who do not respond to existing hormone-based treatments. This research adds critical knowledge about how aggressive prostate cancers develop and persist despite therapy. The identification of RSPO2 as a key driver of disease progression opens new possibilities for treatment strategies aimed at improving outcomes for patients with advanced prostate cancer. DOI - https://doi.org/10.18632/oncotarget.28758 Correspondence to - Justin Hwang - jhwang@umn.edu Video short - https://www.youtube.com/watch?v=iyu5D_c1dbY Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28758 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, RSPO2, prostate cancer, Wnt signaling, genomics, therapeutics To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Dr. Adam Kinnaird of the University of Alberta joins Dr. Aly-Khan Lalani and Dr. Christopher Wallis to explore the evolution of prostate cancer diagnostics, from the limitations of transrectal ultrasound to the rise of MRI and micro-ultrasound. They unpack key trials, discuss real-world challenges like long MRI wait times in Canada, and examine how micro-ultrasound offers a scalable, point-of-care solution. This can't-miss episode charts a path toward faster and more accurate prostate cancer care.This podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Holly Cotton (breast cancer survivor, nurse, author) and Dewayne Charleston (stage 4 prostate cancer survivor). Topic: Raising awareness and eliminating disparities in Black men’s health, especially prostate cancer. 2. Holly Cotton’s Story Breast cancer survivor and nurse with a master’s degree. Author of Strong More Than Muscles. Uses her survivorship to inspire others and promote health awareness. Advocates for being a “life survivor,” not just a cancer survivor. 3. Rushion McDonald’s Personal Experience Thyroid cancer survivor since 2015. Shares how the diagnosis changed his perspective on life and purpose. Uses his platform to raise awareness and encourage proactive health decisions. 4. Dwayne’s Journey Diagnosed with stage 4 prostate cancer at age 46. All 16 biopsy samples came back positive. Told by MD Anderson urologist Dr. Lewis Sisler that only prayer could help. Fought cancer for 14 years and founded a prostate cancer awareness foundation. 5. Foundation Mission Educates Black men on prostate cancer, clinical trials, and health disparities. Addresses emotional, sexual, financial, and relational impacts of cancer. Aims to break silence and stigma around men’s health issues. 6. Breast Cancer Awareness vs. Prostate Cancer Awareness Holly explains the success of “Go Pink” campaigns for breast cancer. Dewayne and Holly aim to replicate that success with “Go Blue” for prostate cancer. Goal: Encourage men to prioritize their own health and get tested. 7. Community Impact Importance of storytelling and visibility at events like HBCU games. Emphasis on legacy, education, and proactive health care. Holly and Dewayne’s collaboration bridges gender and cancer awareness gaps. 8. Closing Rushon thanks guests for their advocacy and friendship. Encourages listeners to lead with their gifts and keep winning.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Holly Cotton (breast cancer survivor, nurse, author) and Dewayne Charleston (stage 4 prostate cancer survivor). Topic: Raising awareness and eliminating disparities in Black men’s health, especially prostate cancer. 2. Holly Cotton’s Story Breast cancer survivor and nurse with a master’s degree. Author of Strong More Than Muscles. Uses her survivorship to inspire others and promote health awareness. Advocates for being a “life survivor,” not just a cancer survivor. 3. Rushion McDonald’s Personal Experience Thyroid cancer survivor since 2015. Shares how the diagnosis changed his perspective on life and purpose. Uses his platform to raise awareness and encourage proactive health decisions. 4. Dwayne’s Journey Diagnosed with stage 4 prostate cancer at age 46. All 16 biopsy samples came back positive. Told by MD Anderson urologist Dr. Lewis Sisler that only prayer could help. Fought cancer for 14 years and founded a prostate cancer awareness foundation. 5. Foundation Mission Educates Black men on prostate cancer, clinical trials, and health disparities. Addresses emotional, sexual, financial, and relational impacts of cancer. Aims to break silence and stigma around men’s health issues. 6. Breast Cancer Awareness vs. Prostate Cancer Awareness Holly explains the success of “Go Pink” campaigns for breast cancer. Dewayne and Holly aim to replicate that success with “Go Blue” for prostate cancer. Goal: Encourage men to prioritize their own health and get tested. 7. Community Impact Importance of storytelling and visibility at events like HBCU games. Emphasis on legacy, education, and proactive health care. Holly and Dewayne’s collaboration bridges gender and cancer awareness gaps. 8. Closing Rushon thanks guests for their advocacy and friendship. Encourages listeners to lead with their gifts and keep winning.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Holly Cotton (breast cancer survivor, nurse, author) and Dewayne Charleston (stage 4 prostate cancer survivor). Topic: Raising awareness and eliminating disparities in Black men’s health, especially prostate cancer. 2. Holly Cotton’s Story Breast cancer survivor and nurse with a master’s degree. Author of Strong More Than Muscles. Uses her survivorship to inspire others and promote health awareness. Advocates for being a “life survivor,” not just a cancer survivor. 3. Rushion McDonald’s Personal Experience Thyroid cancer survivor since 2015. Shares how the diagnosis changed his perspective on life and purpose. Uses his platform to raise awareness and encourage proactive health decisions. 4. Dwayne’s Journey Diagnosed with stage 4 prostate cancer at age 46. All 16 biopsy samples came back positive. Told by MD Anderson urologist Dr. Lewis Sisler that only prayer could help. Fought cancer for 14 years and founded a prostate cancer awareness foundation. 5. Foundation Mission Educates Black men on prostate cancer, clinical trials, and health disparities. Addresses emotional, sexual, financial, and relational impacts of cancer. Aims to break silence and stigma around men’s health issues. 6. Breast Cancer Awareness vs. Prostate Cancer Awareness Holly explains the success of “Go Pink” campaigns for breast cancer. Dewayne and Holly aim to replicate that success with “Go Blue” for prostate cancer. Goal: Encourage men to prioritize their own health and get tested. 7. Community Impact Importance of storytelling and visibility at events like HBCU games. Emphasis on legacy, education, and proactive health care. Holly and Dewayne’s collaboration bridges gender and cancer awareness gaps. 8. Closing Rushon thanks guests for their advocacy and friendship. Encourages listeners to lead with their gifts and keep winning.

Losing a part of yourself to cancer treatment doesn't mean losing your sense of intimacy, confidence, or vitality.In this episode, Dr. Stephen Petteruti speaks directly to men who've had prostate surgery, radiation, or other therapies that impacted their sexual health. He offers clear, practical strategies—from penile rehabilitation with pumps and shockwave therapy to performance support with PDE-5 inhibitors, Trimix, and even libido-stimulating peptides like PT-141. This episode goes far beyond prescriptions. It's about reclaiming a vital part of who you are. Tune in NOW: Sex After Prostate Cancer: How to Save Your Sex Life.Enjoy the podcast? Subscribe and leave a 5-star review!Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: www.intellectualmedicine.com Website: https://www.theprostateprotocol.com/ YouTube: https://www.youtube.com/@intellectualmedicine LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: instagram.com/intellectualmedine Consultation: https://www.theprostateprotocol.com/book-a-consultation Store: https://www.theprostateprotocol.com/store Community: https://www.theprostateprotocol.com/products/communities/v2/fightcancerlikeaman/home  Disclaimer:  The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com

Sweet poison? New doubts cast over safety of erythritol; Is Greek yogurt a good way to enhance protein intake? Comparing whey, soy, and pea protein isolates; When taking supplements, is it advisable to take periodic breaks to enhance their effectiveness? Tommy John surgery pioneer and longtime Mets medical director dies at 68; Ivermectin, once branded useless “horse paste,” may prove a new weapon against malaria; New findings challenge notion that humans and apes share 99% of their DNA.

Flowers have been left at the scene of a crash in Herne Bay following the death of a motorcyclist.The man in his 20s was riding along Reculver Road when he was involved in a collision near the junction with Terminus Drive in the early hours of Saturday.Also in today's podcast, an MP has raised concerns about plans for a housing development on land in Rainham.An application for hundreds of homes on an orchard off Pump Lane was previously rejected - but now the land's been included in the council's Local Plan.Hear from Naushabah Khan who has joined residents at a protest.A Medway man with incurable prostate cancer is setting off on a 588 mile walk as he campaigns for a national screening programme.Paul Dennington was told in March 2021 he has five to eight years to live. He's been chatting about his challenge to raise money for Prostate Cancer UK.A Rochester dog owner faces a hefty bill for surgery after it was discovered his pet is a hermaphrodite.Lincoln has been suffering from a number of health problems in recent months and scans found he had both male and female reproductive organs.And in sport, it was a point for Gillingham at the weekend to start the new season.It finished 1-1 at Accrington Stanley on Saturday - hear reaction from manager Gareth Ainsworth and midfielder Armani Little.

UCSF researchers June Chan and Stacey Kenfield share evidence-based strategies for improving prostate cancer outcomes through exercise and diet. They highlight studies showing that physical activity—including resistance and high-intensity interval training—is linked to lower risk of prostate cancer progression and death. They discuss plant-based diets, dietary indices, and specific foods like tomatoes, fish, and nuts, along with the benefits of substituting plant oils for butter. Their analysis includes findings on racial disparities and underscores the need for inclusive research. They also describe current clinical trials exploring lifestyle tools and offer guidance on navigating diet and exercise choices during cancer survivorship. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40808]

UCSF researchers June Chan and Stacey Kenfield share evidence-based strategies for improving prostate cancer outcomes through exercise and diet. They highlight studies showing that physical activity—including resistance and high-intensity interval training—is linked to lower risk of prostate cancer progression and death. They discuss plant-based diets, dietary indices, and specific foods like tomatoes, fish, and nuts, along with the benefits of substituting plant oils for butter. Their analysis includes findings on racial disparities and underscores the need for inclusive research. They also describe current clinical trials exploring lifestyle tools and offer guidance on navigating diet and exercise choices during cancer survivorship. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40808]

UCSF researchers June Chan and Stacey Kenfield share evidence-based strategies for improving prostate cancer outcomes through exercise and diet. They highlight studies showing that physical activity—including resistance and high-intensity interval training—is linked to lower risk of prostate cancer progression and death. They discuss plant-based diets, dietary indices, and specific foods like tomatoes, fish, and nuts, along with the benefits of substituting plant oils for butter. Their analysis includes findings on racial disparities and underscores the need for inclusive research. They also describe current clinical trials exploring lifestyle tools and offer guidance on navigating diet and exercise choices during cancer survivorship. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40808]

UCSF researchers June Chan and Stacey Kenfield share evidence-based strategies for improving prostate cancer outcomes through exercise and diet. They highlight studies showing that physical activity—including resistance and high-intensity interval training—is linked to lower risk of prostate cancer progression and death. They discuss plant-based diets, dietary indices, and specific foods like tomatoes, fish, and nuts, along with the benefits of substituting plant oils for butter. Their analysis includes findings on racial disparities and underscores the need for inclusive research. They also describe current clinical trials exploring lifestyle tools and offer guidance on navigating diet and exercise choices during cancer survivorship. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40808]

In this episode, our guest, Dr. Andrew Armstrong of Duke University, discusses recent advances that men should know to overcome prostate cancer. We ask about former President Joe Biden's diagnosis. What does it mean to have Stage IV prostate cancer and a Gleason score of 9? News outlets have reported that Mr. Biden's previous prostate […]

In this episode of OncTimes Talk, we chat with Tom Hulsey—athlete, author, and prostate cancer survivor—about the life-altering moment he received his diagnosis on his birthday, and how it set him on a path of resilience, advocacy, and renewed purpose. Tom opens up about the emotional toll of staying silent, the power of mindset in healing, and how facing both cancer and heart disease reshaped his outlook on life. He also shares insights from his work with medical research programs and offers powerful advice for men navigating their own health journeys. This is a conversation about vulnerability, strength, and the will to turn pain into purpose.

Ms Kathleen D Burns from City of Hope Comprehensive Cancer Center in Duarte, California, discusses nursing considerations in the care of patients with prostate cancer. NCPD information and select publications here.

Dr Bill Nelson and Dr Michael Carducci discuss using Prostate-Specific Membrane Antigen (PSMA) targeted therapies to detect and treat prostate cancer.

Featuring an interview with Ms Kathleen D Burns, including the following topics: Case: A man in his early 70s with metastatic hormone-sensitive prostate cancer who received an androgen receptor inhibitor in combination with androgen deprivation therapy (0:00) Case: A man in his early 70s with metastatic castration-resistant prostate cancer (mCRPC) who received olaparib in combination with abiraterone (23:20) Case: A man in his mid 70s with mCRPC who received lutetium Lu 177 vipivotide tetraxetan (33:44) NCPD information and select publications

In this episode of Onc Now, host Jonathan Sackier is joined by Stephen Freedland, Surgical Oncologist at Cedars-Sinai Medical Center, Los Angeles, California, USA, to discuss the intersections of biology, behaviour, and bias in prostate cancer. From diet and exercise to disparities in outcomes and promising data on enzalutamide, Freedland challenges assumptions and advocates for a more holistic, equitable approach to care.  Timestamps   01:20 – Background and clinical journey 02:39 – Cancer myths: what needs busting 03:22 – Lifestyle's role in prostate cancer 05:18 – One habit all cancer patients should adopt 06:39 – Yes or No round 10:30 – Diet, obesity, and exercise: the data 13:25 – Mediterranean diet and outcomes 15:30 – Predictive lifestyle factors 16:19 – Racial disparities and root causes 18:35 – Gender-affirming treatment and prostate cancer in trans women 23:20 – Enzalutamide: latest data and developments 25:51 – Broader therapeutic landscape 28:40 – Risk of recurrence 30:19 – Advice for young oncologists 34:00 – Three wishes for the future of prostate cancer care 

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about Northwestern Memorial Hospital being named one of the best hospitals in the U.S., Cubs great Ryne Sandberg losing his battle to prostate cancer, what we should know about prostate cancer, and a new study that shows being physically active […]

The Idaho Urologic Institute introduced a procedure that gives doctors a non-invasive way to target prostate cancer. 

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about Northwestern Memorial Hospital being named one of the best hospitals in the U.S., Cubs great Ryne Sandberg losing his battle to prostate cancer, what we should know about prostate cancer, and a new study that shows being physically active […]

Prostate cancer is the second most diagnosed cancer among men worldwide and remains a leading cause of cancer-related death. While early forms of the disease can usually be treated successfully, advanced cases remain a major challenge. Scientists have now discovered a new potential way to slow the growth of advanced, treatment-resistant prostate cancer. These results were recently published in Volume 16 of Oncotarget by researchers from the University of Cincinnati College of Medicine. Understanding Advanced Prostate Cancer Early-stage prostate cancer can often be treated successfully. Most treatments work by lowering testosterone levels or blocking the hormone from activating the androgen receptor (AR), which drives cancer growth. In some patients, however, the disease progresses to castration-resistant prostate cancer (CRPC). Even with drastic reductions in testosterone levels, the tumors continue to grow at this stage. CRPC is much more difficult to treat, and current therapies such as hormone blockers or chemotherapy typically extend life by only a few months. One reason for this resistance is that cancer cells often switch to a different form of the androgen receptor called AR-V7. This variant remains permanently active, even without testosterone, making hormone-based drugs less effective. Because of this, new treatment strategies that work independently of hormone levels are needed. The Study: Targeting a New Weakness in Prostate Cancer Cells In the study titled “Targeting PCNA/AR interaction inhibits AR-mediated signaling in castration resistant prostate cancer cells,” researchers Shan Lu and Zhongyun Dong from the University of Cincinnati College of Medicine investigated a new way to block CRPC growth. Full blog - https://www.oncotarget.org/2025/07/29/a-new-way-to-target-resistant-prostate-cancer-cells/ Paper DOI - https://doi.org/10.18632/oncotarget.28722 Correspondence to - Zhongyun Dong - dongzu@ucmail.uc.edu Video short - https://www.youtube.com/watch?v=fiJWZ_fKxgs Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28722 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PCNA, androgen receptor, PCNA inhibitors, AR splicing variants, CRPC To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about Northwestern Memorial Hospital being named one of the best hospitals in the U.S., Cubs great Ryne Sandberg losing his battle to prostate cancer, what we should know about prostate cancer, and a new study that shows being physically active […]

Dr Akila Viswanathan speaks with Dr Sophia Kamran from Harvard Medical School and Dr Constantinos Zamboglou from the German Oncology Center about the latest edition of Seminars in Radiation Oncology focusing on new treatments for advanced prostate cancer.

On this episode host Jonathan Chance talks with Dr. Munir Ghesani, who is a Nuclear Oncologist and the Chief Medical Officer for United Theranostics about (RPT) radiopharmaceutical therapy, which is a treatment for prostate cancer. During the podcast Jonathan and Dr. Ghesani talk about:·       What is Theranostics and which prostate cancer patients is are candidates for radiopharmaceuticals.·       How is the therapy administered and how the effectiveness is determined.·       Are there side effects and how does it compare to alpha emitter radiation therapy.·       Plutvicto treatment for metastatic prostate cancer.·       The Vision and PSMA Fore trials of targeted radioligand therapy in patients with prostate cancer.·       What the future looks like for cancer treatment.Prostate Cancer Aware is a copyrighted production. No content maybe rebroadcast or reproduced without the expressed written consent of the Friedman Sidrow Foundation. For more information about prostate cancer, the PSA test, men's health and Jonathan's inspiring new book Unaware, which is about his battle with prostate cancer. Visit our website at: https://www.iknowmypsa.org Email us at: https://www.iknowmypsa.org/contactus/ Follow Prostate Cancer Aware on social media at: Facebook - https://www.facebook.com/iknowmypsa Twitter - https://twitter.com/iknowmypsa or @iknowmypsa Thank you for listening! Remember, Stay Aware and Stay Healthy.™

Dr. Steven Seyedin presents an overview of PSA recurrence and risk factors for assessment. A PSA test is a blood test used to detect prostate-specific antigen (PSA) levels in the blood, which can be elevated in cases of prostate cancer and is a common screening tool. He explains how PET, CT, and MRI work, highlighting the precision of PSA PET in detecting cancer spread by targeting PSA proteins on tumor cells. This imaging method combines PET and CT to reveal metastatic disease with greater accuracy than traditional scans. Seyedin addresses the strengths of different imaging agents, emphasizing that access, not brand, is key. He also cautions against false positives, especially in bone lesions, which can mislead diagnosis. By improving staging accuracy, PSA PET supports better treatment planning and outcomes. Ongoing studies explore its use earlier in diagnosis, potentially replacing biopsy or MRI in select cases. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40805]

Prostate cancer and its treatments can significantly impact bone health, increasing the risk of fractures and weakening the immune system. Dr. Terence Friedlander explains how hormone therapy, radiation, and chemotherapy contribute to bone loss and highlights the importance of regular monitoring. He reviews the role of bone-building cells and the effects of osteopenia and osteoporosis, conditions that become more common with age and can be worsened by cancer therapies. Friedlander outlines tools like the Dexa scan and FRAX calculator to assess bone density and fracture risk, and discusses prevention strategies, including adequate calcium and vitamin D intake, weight-bearing exercise, and the use of medications like bisphosphonates and denosumab. He emphasizes proactive bone care for men with prostate cancer to help reduce complications and improve outcomes. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40812]

Dr. Steven Seyedin presents an overview of PSA recurrence and risk factors for assessment. A PSA test is a blood test used to detect prostate-specific antigen (PSA) levels in the blood, which can be elevated in cases of prostate cancer and is a common screening tool. He explains how PET, CT, and MRI work, highlighting the precision of PSA PET in detecting cancer spread by targeting PSA proteins on tumor cells. This imaging method combines PET and CT to reveal metastatic disease with greater accuracy than traditional scans. Seyedin addresses the strengths of different imaging agents, emphasizing that access, not brand, is key. He also cautions against false positives, especially in bone lesions, which can mislead diagnosis. By improving staging accuracy, PSA PET supports better treatment planning and outcomes. Ongoing studies explore its use earlier in diagnosis, potentially replacing biopsy or MRI in select cases. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40805]

Prostate cancer and its treatments can significantly impact bone health, increasing the risk of fractures and weakening the immune system. Dr. Terence Friedlander explains how hormone therapy, radiation, and chemotherapy contribute to bone loss and highlights the importance of regular monitoring. He reviews the role of bone-building cells and the effects of osteopenia and osteoporosis, conditions that become more common with age and can be worsened by cancer therapies. Friedlander outlines tools like the Dexa scan and FRAX calculator to assess bone density and fracture risk, and discusses prevention strategies, including adequate calcium and vitamin D intake, weight-bearing exercise, and the use of medications like bisphosphonates and denosumab. He emphasizes proactive bone care for men with prostate cancer to help reduce complications and improve outcomes. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40812]

“Next-generation sequencing, or NGS, can be used to help us determine if the patient has specific biomarkers we can identify and use to target for treatment. Certain findings can tell us if a particular treatment might work for that patient, and we can see if there are any genetic variants we might have a biomarker targeted agent to use to treat them with,” ONS member Jackie Peterson, MSN, RN, OCN®, NE-BC, MBA, ambulatory nurse manager at the University of Chicago Medical Center in Illinois, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about prostate cancer and biomarker testing.  This podcast is sponsored by AstraZeneca and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod    Licensed under Creative Commons by Attribution 3.0   Episode Notes This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 180: Learn How Nurse Practitioners Use Biomarker Testing in Cancer Care ONS Voice articles: An Oncology Nurse's Guide to Cascade Testing Genetic Disorder Reference Sheet: BRCA1 and BRCA2 Hereditary Disorders Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Germline and Somatic Variants: What Is the Difference? Help Patients Understand Genomic Variants of Unknown Significance Prostate Cancer Clinical Trials Don't Reflect Racial Diversity—And It's Getting Worse Over Time Prostate Cancer Disparities Disappear With Equal Access to Care Prostate Cancer Prevention, Screening, Treatment, and Survivorship Recommendations The Case of the Genomics-Guided Care for Prostate Cancer ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing articles: Metastatic Prostate Cancer: An Update on Treatments and a Review of Patient Symptom Management Prostate Cancer: How Nurse Practicioners Can Aid in Disease Diagnosis and Management Oncology Nursing Forum article: Identification of Symptom Profiles in Prostate Cancer Survivors Other ONS Resources: Biomarker Database (refine by prostate cancer or specific biomarkers) Clinical tool/case study: Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Genomics and Precision Oncology Learning Library Huddle Card: Genomic Biomarkers Infographic: Talking to Your Patient About a Germline Variant of Uncertain Significance (VUS) American Cancer Society - Genetic Testing and Counseling for Prostate Cancer Risk American Cancer Society - Prostate Cancer Clinicaltrials.gov National Cancer Institute - Prostate Cancer National Comprehensive Cancer Network ZERO Prostate Cancer To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From This Episode “Some of the risk factors for developing prostate cancer include age, race, family history, and certain genetic changes or variants. Prostate cancer has some hereditary components, but most prostate cancer occurs in men without any significant family history of it.” TS 1:31 “Key biomarkers include PSA and prostate cancer gene 3, which is PCA3, and prostate-specific membrane antigen, or PSMA. Other biomarkers that are important for us to test include BRCA1, BRCA2, and Lynch syndrome–associated genes, which are MLH1, MSH2, MSH6, PMS2, and EPCAM. Biomarkers can be collected via your blood, urine, saliva, or tissue samples, so these are different ways that we can test and look for biomarkers in our patients.” TS 3:24 “It does matter how advanced the disease is. Usually, for our castrate-sensitive patients, they respond better to androgen deprivation therapy because that really is slowing down the growth of the cancer by reducing the available testosterone that the cancer needs to grow. Whereas our patients that are more advanced and have castrate-resistant prostate cancer, that cancer will continue to grow despite having the lowered testosterone levels, so they might need additional layers of treatment to really get their cancer under control.” TS 7:50 “When I talk to [patients] about biomarker testing, I tell them it's another tool in our toolbox that we can use to help us determine if they might benefit from other therapy options now or in the future. I tell them that sometimes we'll get a report back with a variant of unknown significance, and basically that means that we don't really know whether or not this has an impact on their health or risk factors for the disease. That can sometimes be a little bit of a concern for these patients, so we just have to reassure them that we're continually doing research around biomarker testing. The science is always advancing, so if there's something that [researchers] find in the future, we'll make them aware of that.” TS 9:08 “One of the biggest topics I think about is the inequity that exists in biomarker testing and research, especially surrounding the African American population. When these tests were developed, that population really wasn't studied as much, so there's not a lot of good data yet to make a decision or impact on those patients and that population.” TS: 12:30

In this episode of the Dr. Geo Prostate Podcast, Dr. Geo welcomes Dr. Mohit Khera, a globally recognized leader in men's health, Professor of Urology and Director of the Executive Health Program at Baylor College of Medicine. With over 160 peer-reviewed publications and decades of clinical experience in testosterone therapy, male infertility, and prostate health, Dr. Khera shares cutting-edge insights on testosterone replacement therapy (TRT), including the rise of oral testosterone like Kyzatrex, and the evolving understanding of testosterone's relationship to prostate cancer.Whether you're considering TRT, recovering from prostate cancer, or supporting a loved one's health journey, this conversation brings clarity to one of men's most pressing health topics.What You'll Learn:The 4 C's framework to determine the best TRT option:Cost, Compliance, Convenience, ConcentrationWhy oral testosterone (Kyzatrex, Tlando, Jatenzo) is gaining traction—and what makes them differentHow Kyzatrex may help preserve fertility by reducing gonadotropin suppressionWhat the TRAVERSE trial revealed about TRT and cardiovascular safetyWhy low testosterone may be linked to more aggressive prostate cancerWhat the latest science says about BAT (Bipolar Androgen Therapy) for advanced prostate cancerThe truth about testosterone's impact on BPH and urinary symptomsWhy total testosterone isn't enough—labs like SHBG, DHT, estradiol, and free testosterone matterKey Insights:TRT doesn't cause prostate cancer — and may even have protective effects in some men.Testosterone is the best barometer of male health—predicting cardiovascular risk, mood, bone density, and more.BAT (Bipolar Androgen Therapy) is showing promise in treating advanced prostate cancer in specific scenarios.Avoid unnecessary aromatase inhibitors and DHT blockers unless clinically indicated.

UCSF's Dr. Cornelia Ding demystifies the prostate cancer pathology report and explains how to read and understand it. The report contains five key sections: patient information, diagnosis and comments, gross description, and any addendums or amendments. It serves multiple purposes—as a medical, legal, and clinical communication tool—and often contains technical language not written for patients. Dr. Ding walks through important terminology such as Gleason score, Grade Groups, and specific diagnostic patterns like intraductal carcinoma, emphasizing how each affects risk assessment and treatment planning. Patients are encouraged to focus on the diagnosis and comment sections and to discuss any unclear details with their doctors. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40797]

UCSF's Dr. Cornelia Ding demystifies the prostate cancer pathology report and explains how to read and understand it. The report contains five key sections: patient information, diagnosis and comments, gross description, and any addendums or amendments. It serves multiple purposes—as a medical, legal, and clinical communication tool—and often contains technical language not written for patients. Dr. Ding walks through important terminology such as Gleason score, Grade Groups, and specific diagnostic patterns like intraductal carcinoma, emphasizing how each affects risk assessment and treatment planning. Patients are encouraged to focus on the diagnosis and comment sections and to discuss any unclear details with their doctors. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40797]

UCSF's Dr. Cornelia Ding demystifies the prostate cancer pathology report and explains how to read and understand it. The report contains five key sections: patient information, diagnosis and comments, gross description, and any addendums or amendments. It serves multiple purposes—as a medical, legal, and clinical communication tool—and often contains technical language not written for patients. Dr. Ding walks through important terminology such as Gleason score, Grade Groups, and specific diagnostic patterns like intraductal carcinoma, emphasizing how each affects risk assessment and treatment planning. Patients are encouraged to focus on the diagnosis and comment sections and to discuss any unclear details with their doctors. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40797]

UCSF's Dr. Cornelia Ding demystifies the prostate cancer pathology report and explains how to read and understand it. The report contains five key sections: patient information, diagnosis and comments, gross description, and any addendums or amendments. It serves multiple purposes—as a medical, legal, and clinical communication tool—and often contains technical language not written for patients. Dr. Ding walks through important terminology such as Gleason score, Grade Groups, and specific diagnostic patterns like intraductal carcinoma, emphasizing how each affects risk assessment and treatment planning. Patients are encouraged to focus on the diagnosis and comment sections and to discuss any unclear details with their doctors. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40797]

AUA2025: Incorporating Genomic Testing and Advanced Imaging for Prostate Cancer Into Your Practice CME Available: https://auau.auanet.org/node/43029 At the conclusion of this activity, participants will be able to: 1. Describe the research that led to the approval of genomic testing for prostate cancer and the implementation of advanced imaging for prostate cancer 2. Order appropriate genomic testing and advanced imaging based on a patient's unique clinical situation 3. State the NCCN guidelines for genomic testing and advanced imaging for prostate cancer 4. Discern the different prognostic endpoints provided by various genomic tests 5. Recognize candidates for, and implications of, germline testing for prostate cancer. ACKNOWLEDGEMENTS: This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. UCSF's Dr. Matthew Cooperberg highlights a shift away from overdiagnosis and overtreatment of low-risk cancers, focusing instead on identifying aggressive disease through tools like MRI and advanced biomarker tests. A new “smarter screening” model now guides primary care, recommending long testing intervals for men with low PSA levels. While active surveillance has increased nationally, significant variation in care remains, and racial disparities—especially for Black men—persist. Patients are encouraged to take time in making treatment decisions, as prostate cancer often progresses slowly and allows for thoughtful, personalized care. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40796]

Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. UCSF's Dr. Matthew Cooperberg highlights a shift away from overdiagnosis and overtreatment of low-risk cancers, focusing instead on identifying aggressive disease through tools like MRI and advanced biomarker tests. A new “smarter screening” model now guides primary care, recommending long testing intervals for men with low PSA levels. While active surveillance has increased nationally, significant variation in care remains, and racial disparities—especially for Black men—persist. Patients are encouraged to take time in making treatment decisions, as prostate cancer often progresses slowly and allows for thoughtful, personalized care. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40796]

Garry and Tim discuss the Legends Game for Prostate Cancer, where Tim will be coaching the Vics. What is some advice garry has for him - plus they discuss some memories from past LEgends games. Do media people within footy have a bias towards people they are friendly with? And we chat with Joe from Peninsula Kubota. For feedback and questions, email joel.brooks@sen.com.au. Learn more about your ad choices. Visit megaphone.fm/adchoices

Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. UCSF's Dr. Matthew Cooperberg highlights a shift away from overdiagnosis and overtreatment of low-risk cancers, focusing instead on identifying aggressive disease through tools like MRI and advanced biomarker tests. A new “smarter screening” model now guides primary care, recommending long testing intervals for men with low PSA levels. While active surveillance has increased nationally, significant variation in care remains, and racial disparities—especially for Black men—persist. Patients are encouraged to take time in making treatment decisions, as prostate cancer often progresses slowly and allows for thoughtful, personalized care. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40796]

Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. UCSF's Dr. Matthew Cooperberg highlights a shift away from overdiagnosis and overtreatment of low-risk cancers, focusing instead on identifying aggressive disease through tools like MRI and advanced biomarker tests. A new “smarter screening” model now guides primary care, recommending long testing intervals for men with low PSA levels. While active surveillance has increased nationally, significant variation in care remains, and racial disparities—especially for Black men—persist. Patients are encouraged to take time in making treatment decisions, as prostate cancer often progresses slowly and allows for thoughtful, personalized care. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40796]

Dr Rahul Aggarwal and Dr William K Oh and nurse practitioners Ms Monica Averia and Ms Kathleen D Burns discuss the current treatment landscape for prostate cancer and protocols to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.

BUFFALO, NY – July 14, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 25, 2025, titled “Hypoxia induced lipid droplet accumulation promotes resistance to ferroptosis in prostate cancer.” In this study, researchers led by Shailender S. Chauhan and Noel A. Warfel from the University of Arizona discovered that prostate cancer cells survive treatment by storing fats in tiny cellular compartments when oxygen levels are low. This process makes the cancer cells less vulnerable to a type of cell death known as ferroptosis. The findings provide new insight into why prostate tumors often resist therapies and suggest potential strategies to improve treatment outcomes. This study focused on ferroptosis, a form of programmed cell death that relies on iron and lipid oxidation to destroy cancer cells. Researchers tested prostate cancer cells under normal and low oxygen conditions and found that hypoxia, or reduced oxygen levels, allowed cancer cells to build up lipid droplets (LD). These structures act as storage units for fats, shielding cancer cells from oxidative damage and preventing ferroptosis from occurring. The researchers found that this adaptation of prostate cancer cells made them less sensitive to ferroptosis-inducing drugs like Erastin and RSL3, even when these drugs were combined for a stronger effect. The team also reported that hypoxia caused significant changes in lipid metabolism, decreasing the availability of specific fatty acids that normally promote ferroptosis. “Transcriptomic analysis revealed that hypoxia significantly reduced the expression of genes related to incorporating polyunsaturated fatty acids into phospholipids (ACSL4, LPCAT3), and parallel lipidomic analysis demonstrated that hypoxia significantly decreased the levels of the ferroptosis-prone lipid class, phosphatidylethanolamine (PE) and increased production of neutral lipid species, cholesteryl ester (ChE (22:5)) and triglycerides (TG(48:1), TG:(50:4), and TG(58:4)).” This research highlights the importance of the tumor microenvironment, particularly oxygen levels, in shaping how cancer cells respond to therapy. By altering their metabolism and storing lipids, prostate tumors may evade treatments designed to trigger ferroptosis. These findings underscore the need to develop new strategies targeting LD dynamics or lipid metabolism to overcome this resistance. Understanding how prostate cancer (Pca) adapts to survive in hypoxic conditions offers a potential avenue for improving therapies. For example, preventing lipid accumulation in cancer cells or releasing stored fats may restore their sensitivity to ferroptosis and improve the effectiveness of current therapies. This approach could have broader implications for treating other solid tumors that share similar metabolic features. DOI - https://doi.org/10.18632/oncotarget.28750 Correspondence to - Noel A. Warfel - warfelna@arizona.edu, and Shailender S. Chauhan - shailenderc@arizona.edu Video short - https://www.youtube.com/watch?v=xFypDT4ALmc Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28750 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, hypoxia, lipid droplets, ferroptosis, resistance, prostate To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

What if artificial intelligence could help save your erections during prostate cancer surgery?In this groundbreaking episode of the Dr. Geo Prostate Podcast, Dr. Geo sits down with world-renowned urologist and sexual health pioneer Dr. Arthur "Bud" Burnett from Johns Hopkins. Together, they discuss an exciting new frontier in men's health: using AI and intraoperative neuromonitoring to preserve erectile function during prostate cancer surgery.Dr. Burnett shares his four decades of experience and explains how advanced techniques — including real-time nerve mapping and AI-guided signals during surgery — are transforming outcomes for men. Imagine a future where surgeons can “see” and protect the exact nerves critical for erections, like having a GPS guiding them in real time.They also dive into:✅ The evolution of erectile dysfunction treatments — from Yohimbine to Viagra and beyond✅ The history and future of penile implants, including the possibility of app-controlled devices✅ Why nerve-sparing techniques alone may not be enough to preserve function after prostatectomy✅ How AI and precision medicine are changing surgical outcomes and offering men more hopePlus, Dr. Burnett discusses upcoming clinical trials and how men can potentially participate today at Johns Hopkins.

A team of researchers from the Te Whai Ao Dodd-Walls Centre have developed a potential gamechanger in the detection and diagnosis of prostate cancer. 

Dr. Hao Nguyen presents focal therapy as a promising treatment option for carefully selected prostate cancer patients, especially those with intermediate-risk, localized disease. Unlike whole-gland treatments, focal therapy targets only the tumor while preserving healthy tissue, reducing the risk of side effects like urinary or sexual dysfunction. UCSF offers multiple approaches—high-intensity focused ultrasound, cryotherapy, and irreversible electroporation—selected based on tumor location and anatomy. Dr. Nguyen emphasizes the importance of precise imaging, MRI fusion biopsy, and genomic testing for patient selection and treatment planning. Early outcomes show encouraging results, with most patients avoiding surgery or radiation within two years and maintaining quality of life. While not yet standard first-line care, focal therapy is gaining traction through research and expert consensus. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40804]

We often panic at the word cancer. For men diagnosed with prostate cancer, it can feel like a threat to their very identity. Many fear it signals the end of their masculinity. But what if there's a better, bolder way to approach treatment? Stephen Petteruti, DO, empowers his patients to “fight prostate cancer like a […]

Last month, former President Joe Biden announced that he had been diagnosed with an aggressive form of prostate cancer. The news sparked a larger conversation about what exactly the best practices are to screen for prostate cancer. Turns out, it's more complicated than it might seem. Host Ira Flatow is joined by oncologist Matthew Cooperberg and statistician Andrew Vickers, who studies prostate cancer screening, to help unpack those complexities.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.